Investing.com - RVL Pharmaceuticals reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
RVL Pharmaceuticals announced earnings per share of $-0.160 on revenue of $10.02M. Analysts polled by Investing.com anticipated EPS of $-0.160 on revenue of $10.03M.
RVL Pharmaceuticals shares are down 53.92% from the beginning of the year , still down 51.84% from its 52 week high of $2.99 set on Wednesday, September 14, 2022.
RVL Pharmaceuticals follows other major Healthcare sector earnings this month
RVL Pharmaceuticals's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar